Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. (RANI): 11 pipeline candidates · 2 upcoming catalysts · ~10 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.7 months
D/E 0.58
Lead: Phase 3
11 candidates
2 upcoming, next in ~2297d
N/A
A transparent, data-derived signal for Rani Therapeutics Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$105.2M
Cash
$9.8M
Quarterly Burn
$6.5M
Runway
9.7 mo
Revenue
$1.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| elacestrant | Phase 3 |
| pg-102 | Phase 1 |
| rt-102 | Phase 1 |
| rt-105 | Preclinical |
| rt-111 | Phase 1 |
| rt-114 | Phase 1 |
| rt-116 | Preclinical |
| rt-117 | Preclinical |
| ze 50-0134 | Phase 1 |
| ze46-0134 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$25.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 9,245,134 | $6.8M |
| ra capital management, l.p. | 8,500,000 | $6.2M |
| samsara biocapital, llc | 8,500,000 | $6.2M |
| susquehanna international group, llp | 1,437,822 | $1.1M |
| geode capital management, llc | 903,298 | $664K |
| blackrock, inc. | 556,889 | $409K |
| nan fung group holdings ltd | 493,584 | $363K |
| 683 capital management, llc | 487,168 | $358K |
| vanguard fiduciary trust co | 455,050 | $334K |
| millennium management llc | 405,669 | $298K |
Showing top 10 of 71 institutional holders of Rani Therapeutics Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rani Therapeutics Holdings, Inc.'s pipeline?
Rani Therapeutics Holdings, Inc. (RANI) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rani Therapeutics Holdings, Inc.'s lead drug candidate?
Rani Therapeutics Holdings, Inc.'s most advanced tracked candidate is elacestrant (Phase 3) for Breast Cancer.
What is Rani Therapeutics Holdings, Inc.'s next catalyst?
Rani Therapeutics Holdings, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor" — expected October 1, 2032.
What is Rani Therapeutics Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rani Therapeutics Holdings, Inc. has approximately 9.7 months of cash runway.
What is Rani Therapeutics Holdings, Inc.'s market capitalization?
Rani Therapeutics Holdings, Inc.'s market capitalization is approximately $105.2M.
Get the full picture on Rani Therapeutics Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.